ArticleTherapeutics and clinical risk management2022
Diagnostic Value of Serum Levels of IL-22, IL-23, and IL-17 for Idiopathic Pulmonary Fibrosis Associated with Lung Cancer.
Article in Therapeutics and clinical risk management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- Idiopathic pulmonary fibrosis and interleukins: a bibliometric analysis [1999-2025].Journal of thoracic disease · 2026Article
- Regulatory role of IL-17-mediated inflammatory pathways in lung cancer initiation and progression.Discover oncology · 2026Review
- Interleukin-23 in lung and airway diseases: from pathogenesis to precision-guided therapeutic targeting.Frontiers in pharmacology · 2026Review
- Advances in understanding the role of interleukins in pulmonary fibrosis (Review).Experimental and therapeutic medicine · 2025Review
- Serum biomarker changes in pulmonary fibrosis with lung cancer and their correlation with patient survival prognosis.American journal of cancer research · 2025Article
- Comprehensive analyses of immune activity in COVID-19-vaccinated idiopathic pulmonary fibrosis patients.Frontiers in immunology · 2024Article
- Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Correlations between idiopathic pulmonary fibrosis (IPF) and lung cancer have been discussed in many previous studies. In the present work, we evaluated the potential diagnostic value of serum levels of Th17 cell-related cytokines for the detection of lung cancer-associated IPF. Methods: Fifty-six patients who had been diagnosed with lung cancer-associated IPF were enrolled, and 59 patients with lung cancer but without IPF were also enrolled, and 60 healthy volunteers were served as the control group. The expression of IL-22, IL-23, and IL-17 was evaluated by enzyme-linked immunosorbent assay (ELISA) kits. Results: We observed that IL-22, IL-23 as well as IL-17 were significantly increased in the serum of lung cancer patients associated IPF; moreover, the results of ROC curve showed that the expression of IL-22, IL-23 and IL-17 can distinguish the lung cancer patients with lung cancer-associated IPF group; finally, the expression of IL-22, IL-23 and IL-17 was positively correlated with the degree of differentiation and metathesis of the tumor. Conclusion: In conclusion, we first reported that IL-22, IL-23 and IL-17 were elevated in the serum of patients with lung cancer-associated IPF, and our data may provide novel evidence for the prevention and treatment of lung cancer-associated IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.